FineImmune Biotechnology
China
unknown
unknown
Stage
About
FineImmune Biotechnology is a T cell therapy company focused on solving technical bottlenecks in the tumor microenvironment (TME). It has discovered proprietary biomarkers, such as CXCL13, intended as targets for anti-cancer cell therapies including TAL, personalized TCRT and CART.
Explore FineImmune Biotechnology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.